Results 81 to 90 of about 31,625 (291)

Transfusion-related adverse events at the tertiary care center in North India: An institutional hemovigilance effort

open access: yesAsian Journal of Transfusion Science, 2011
Aim: This study was designed to analyze the incidence and spectrum of adverse effects of blood transfusion so as to initiate measures to minimize risks and improve overall transfusion safety in the institute. Materials and Methods: During the period from
Bhattacharya Prasun   +4 more
doaj  

A review of transfusion reaction reports for the year 2008

open access: yes, 2009
Blood transfusion reaction is defined as any adverse manifestation following transfusion of blood or blood products. The symptoms of transfusion reaction range from a mild allergy reaction to a life threatening anaphylactic or haemolytic reaction.
Ismail, Rusmawati   +4 more
core  

ADVERSE EVENTS OF BLOOD TRANSFUSION AND BLOOD SAFETY IN CLINICAL PRACTICE

open access: yes, 2018
Blood transfusions can be lifesaving. The majority are completed without incident. However, every transfusion recipient runs the risk of developing a transfusion reaction or adverse event.
Mudasir Maqbool, Dr. Wardah Shabbir, Dr. Sammia Aamir
core   +1 more source

Preclinical Efficacy and Safety Evaluation of a Novel Controlled‐Expansion ePTFE‐Covered TIPS Stent in a Swine Model

open access: yesPortal Hypertension &Cirrhosis, EarlyView.
This preclinical study evaluated a novel controlled‐expansion expanded polytetrafluoroethylene (ePTFE)‐covered transjugular intrahepatic portosystemic shunt (TIPS) stent in 11 swine, demonstrating 100% technical success, excellent deployability, and durable 6‐month angiographic patency without thrombosis, migration, fracture, or device‐related toxicity.
Yi Xiang   +15 more
wiley   +1 more source

Transfusion [PDF]

open access: yes
BACKGROUND:In 2010, health care facilities in the United States began voluntary enrollment in the National Healthcare Safety Network (NHSN) Hemovigilance Module.

core   +2 more sources

Adverse Transfusion Reactions in Critically Ill Patients

open access: yes, 2014
Although transfusion therapy in the past 30 years has achieved high levels of safety, severe adverse reactions can still complicate a red blood cell, plasma, or platelet transfusion. Adverse events can be either of infectious nature (Infectious Adverse Reactions to Transfusion–IARTs) or noninfectious (NIARTs).
Tomasella, Federica, Mascaretti, Luca G.
openaire   +1 more source

Nonthermal plasma approaches for combating implant‐associated infections: A compendious review

open access: yesVIEW, EarlyView.
Implant‐associated infections pose serious clinical challenges. Non‐thermal plasma (NTP) modifications overcome this bottleneck in distinct ways relative to traditional sterilization methods. Gas‐phase plasmas generate highly energetic species, UV radiation and reactive oxygen/nitrogen species (RONS), which alter the implant surface properties.
A. M. Trimukhe   +8 more
wiley   +1 more source

Adverse reaction after transfusion of Red Blood Cells in a patient aged 97 years - case report

open access: yes, 2021
During hospitalization 97 years old patient had blood transfusion. This procedure lead to overload of cardiovascular system. Pharmacotherapy gradually improved the general condition of the patient. The patient was discharged in a stable state.
Wojtczak, Anna   +7 more
core   +1 more source

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
We report our single‐center experience of transplant outcomes with a busulfan, fludarabine and melphalan‐based conditioning regimen for children < 18 years of age. The regimen was shown to be well tolerated and effective for heavily pretreated children with high‐risk myeloid malignancies prior to allogeneic hematopoietic stem cell transplant.
Mayank Dhamija   +6 more
wiley   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

open access: yesAllergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy